Gliknik
company
About
Gliknik develops therapies for patients with cancer and immune disorders.
- 51 - 100
Highlights
Details
- Last Funding Type
- Corporate Round
- Last Funding Money Raised
- $15M
- Industries
- Biotechnology,Health Care,Medical
- Founded date
- Jan 1, 2007
- Number Of Employee
- 51 - 100
- Operating Status
- Active
Gliknik, Inc., a biopharmaceuticals company, develops therapies for patients with cancer and immune disorders. Its Immunomodulator Platform involves in off-the-shelf peptide drugs that increase CD4, CD8, and antibody immune responses against cancer; Stradomer Platform produces drugs designed to mimic the eficacy of pooled human intravenous immunoglobulin; and Stradobody Platform produces compounds that are similar to moncolonal antibodies for tumor cell killing. The company was founded in 2007 and is based in Baltimore, Maryland.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
1
$15M
Gliknik has raised a total of
$15M
in funding over 2 rounds. Their latest funding was raised on
Feb 19, 2019 from a Corporate Round round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Feb 19, 2019 | Corporate Round | $15M | 1 |
Pfizer
|
— | Detail |
Investors
Number of Lead Investors
Number of Investors
1
1
Gliknik is funded by 1 investors.
Pfizer
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
Pfizer
|
Yes | Corporate Round |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
